Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Lithium formulations

Despite the availability of modified-release lithium formulations for several decades, there continues to be a paucity of information about their efficacy and tolerability compared with less expensive immediate-release formulations (516). [Pg.153]

Gelatin is derived from natural pork and beef products and is present in some lithium formulations. Since certain religions forbid the consumption of gelatin, knowing that it is present in Eskalith capsules and Eskalith CR and absent in Eskalith tablets (not available in the USA) and Lithobid SR might influence prescribing practices... [Pg.153]

A 29-year-old man who overdosed on 8,000 mg of a sustained-release lithium formulation had a serum concentration of 3.12 mmol/l 25 hours later, but only became symptomatic (with vomiting and dizziness) 35 hours later his symptoms resolved with hemodialysis (522). [Pg.155]

In 12 healthy men, there was no food-induced change in the systemic availability of a sustained-release lithium formulation that used an acrylic matrix of Eudragit RSPM as a sustaining agent (694). [Pg.163]

Phillips JD (1991) Bioavailability of lithium formulations. In Birch NJ, ed. Lithium and the Cell Pharmacology and Biochemistry, pp. 317-325. Academic Press, London. [Pg.495]

The following intermediate compounds in some reductions with lithium aluminium hydride have been formulated ... [Pg.878]

As formulated above in terms of spin-orbitals, the Hartree-Fock (HF) equations yield orbitals that do not guarantee that P possesses proper spin symmetry. To illustrate the point, consider the form of the equations for an open-shell system such as the Lithium atom Li. If Isa, IsP, and 2sa spin-orbitals are chosen to appear in the trial function P, then the Fock operator will contain the following terms ... [Pg.462]

Due to the strong ionic nature of lithium trifluoromethanesulfonate, it can increase the conductivity of coating formulations, and thereby enhance the dissipation of static electricity in nonconducting substrates (see Antistatic agents) (25). [Pg.315]

Applications. Polymers with small alkyl substituents, particularly (13), are ideal candidates for elastomer formulation because of quite low temperature flexibiUty, hydrolytic and chemical stabiUty, and high temperature stabiUty. The abiUty to readily incorporate other substituents (ia addition to methyl), particularly vinyl groups, should provide for conventional cure sites. In light of the biocompatibiUty of polysdoxanes and P—O- and P—N-substituted polyphosphazenes, poly(alkyl/arylphosphazenes) are also likely to be biocompatible polymers. Therefore, biomedical appHcations can also be envisaged for (3). A third potential appHcation is ia the area of soHd-state batteries. The first steps toward ionic conductivity have been observed with polymers (13) and (15) using lithium and silver salts (78). [Pg.260]

In addition to the formulation parameters mentioned above, selection of the base used for catalysis has strong implications. Bases commonly used are sodium hydroxide, potassium hydroxide, lithium oxide, calcium hydroxide, barium hy-... [Pg.890]

Elsewhere, in a series of Japanese patents, mixtures of resorcinol + sodium nitrate, glycerine + sodium nitrate, lithium hydroxide + tungstate, etc., have been claimed to be effective. An example of the use of inhibited cooling mixtures of low toxicity is provided by a patent which describes a mixture of silicate-I- polyphosphate -I- a saccharide, e.g. sucrose or fructose, as the inhibitor formulation in a propylene glycol -I- potassium-hydrogen-carbonate mixture used in aluminium cooler boxes for ice-cream. [Pg.800]

Lithium alcohol sulfates are used in carpet-cleaning formulations due to their special foaming characteristics. [Pg.277]

Let us consider lithium as an example. In the usual treatment of this metal a set of molecular orbitals is formulated, each of which is a Bloch function built from the 2s orbitals of the atoms, or, in the more refined cell treatment, from 2s orbitals that are slightly perturbed to satisfy the boundary conditions for the cells. These molecular orbitals correspond to electron energies that constitute a Brillouin zone, and the normal state of the metal is that in which half of the orbitals, the more stable ones, are occupied by two electrons apiece, with opposed spins. [Pg.374]

In a similar manner, treatment of anhydrous rare-earth chlorides with 3 equivalents of lithium 1,3-di-ferf-butylacetamidinate (prepared in situ from di-ferf-butylcarbodiimide and methyllithium) in THF at room temperature afforded LnlMeCfNBuOils (Ln = Y, La, Ce, Nd, Eu, Er, Lu) in 57-72% isolated yields. X-ray crystal structures of these complexes demonstrated monomeric formulations with distorted octahedral geometry about the lanthanide(III) ions (Figure 20, Ln = La). The new complexes are thermally stable at >300°C, and sublime... [Pg.236]

Formulation(s) cps. 300 mg (as sodium salt) nasal drops 2.3 % (as sodium salt) tabl. 200 mg (as lithium salt)... [Pg.2022]

Lithium reacts with copper powder in a copper crucible at 200°C to yield yellow mixed crystals of the variable-phase LiCu4, whose formulation represents a maximum content of Li. A crystalline LiCu4 product is observed on copper surfaces exposed to liquid lithium. ... [Pg.413]

Poetschke (1925) patented a dental silicate powder prepared by fusing zinc silicate with calcium fluoride. This is a kind of silicophosphate cement (Section 6.6). Thomsen (1931) attempted to formulate a water-setting dental cement. Heynemann (1931) included lithium salts in the flux and Brill (1935) included them in the liquid. [Pg.262]

The mechanism of conjugate addition reactions probably involves an initial complex between the cuprate and enone.51 The key intermediate for formation of the new carbon-carbon bond is an adduct formed between the enone and the organocopper reagent. The adduct is formulated as a Cu(III) species, which then undergoes reductive elimination. The lithium ion also plays a key role, presumably by Lewis acid coordination at the carbonyl oxygen.52 Solvent molecules also affect the reactivity of the complex.53 The mechanism can be outlined as occurring in three steps. [Pg.687]

Divalproex sodium is comprised of sodium valproate and valproic acid. The delayed-release and extended-release formulations are converted in the small intestine into valproic add, which is the systemically absorbed form. It was developed as an antiepileptic drug, but also has efficacy for mood stabilization and migraine headaches. It is FDA-approved for the treatment of the manic phase of bipolar disorder. It is generally equal in efficacy to lithium and some other drugs for bipolar mania. It has particular utility in bipolar disorder patients with rapid cycling, mixed mood features, and substance abuse comorbidity. Although not FDA-approved for relapse prevention, studies support this use, and it is widely prescribed for maintenance therapy. Divalproex can be used as monotherapy or in combination with lithium or an antipsychotic drug.31... [Pg.597]

The simple methylidyne compound [HC=Co]+ has been formulated as a CoIV species.1102 The norbornyl anion (nor), as the lithium salt, reacts with CoCl2 to produce the brown, paramagnetic tetrahedral Co(nor)4. This can undergo both reduction (to [Co(nor)4] ) and oxidation (with AgBF4) to what appears to be [Co(nor)4]+, a diamagnetic tetrahedral compound. This remains one of the very few established examples of Cov. [Pg.98]

Vollmer et al. [4] compared the Hg(II) acetate method described in the Code of Federal Regulations for the determination of penicillamine in bulk drug and formulations with (i) a nonaqueous lithium methoxide titration, (ii) a nonaqueous HCLO4 titration, and (iii) a colorimetric method with hydroxylamine. Method (ii) was unsatisfactory for bulk determinations. Method (i) was less precise than the Hg(II) acetate method, but gave satisfactory results for bulk drug and capsule samples. Method (iii) was the only method that gave satisfactory results in the presence of EDTA. [Pg.133]


See other pages where Lithium formulations is mentioned: [Pg.220]    [Pg.247]    [Pg.274]    [Pg.478]    [Pg.69]    [Pg.456]    [Pg.228]    [Pg.365]    [Pg.353]    [Pg.70]    [Pg.903]    [Pg.324]    [Pg.887]    [Pg.149]    [Pg.147]    [Pg.205]    [Pg.619]    [Pg.594]    [Pg.599]    [Pg.599]    [Pg.679]    [Pg.175]    [Pg.309]   
See also in sourсe #XX -- [ Pg.767 ]

See also in sourсe #XX -- [ Pg.767 ]

See also in sourсe #XX -- [ Pg.317 ]




SEARCH



Lithium drug formulations

© 2024 chempedia.info